Role of endothelial dysfunction in coronary artery disease

American Journal of Cardiology

Volumn 79, Issue 12 B, 1997, Pages 2-9

  Abrams, Jonathan ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; ENDOTHELIUM DERIVED RELAXING FACTOR; GLYCERYL TRINITRATE; HYPOCHOLESTEROLEMIC AGENT; ISOSORBIDE 5 NITRATE; MOLSIDOMINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; ORGANIC NITRATE; VASODILATOR AGENT;

CONFERENCE PAPER; CORONARY ARTERY DISEASE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

EID: 0030848225     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00379-2     Document Type: Conference Paper

References (64)

1. Thadani U, Chohan A. Chronic stable angina. Strategies for effective drug therapy. Postgrad Med. 98:1995;175-188.
2. Gersh BJ, Braunwald E, Rutherford JD. Chronic coronary artery disease. Braunwald E. Heart Disease. 1997;1289-1365 WB Saunders, Philadelphia.
3. Mehta JL. Endothelium, coronary vasodilation, and organic nitrates. Am Heart J. 129:1995;382-391.
4. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
5. Myers PR, Al-Swayeh OA, Chone NWS, Bates JN, Harrison DG. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature. 345:1990;161-163.
6. Feelisch M, Brands F, Kelm M. Human endothelial cells bioactivate organic nitrates to nitric oxide: implications for the reinforcement of endothelial defense mechanisms. Eur J Clin Invest. 25:1995;737-745.
7. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC, Selwyn AP. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol. 26:1995;1235-1241.
8. Drexler H, Fischell TA, Pinto FJ, Chenzbraun A, Botas J, Cooke JP, Alderman EL. Effect of L-arginine on coronary endothelial function in cardiac transplant recipients. Relation to vessel wall morphology. Circulation. 89:1994;1615-1623.
9. Kinn JW, Altman JD, Chang MW, Bache RJ. Vasomotor responses of newly developed coronary collateral vessels. Am J Physiol. 271:1996;H490-H497.
10. Frank MW, Harris KR, Ahlin KA, Klocke FJ. Endothelium-derived relaxing factor (nitric oxide) has a tonic vasodilating action on coronary collateral vessels. J Am Coll Cardiol. 27:1996;658-663.
11. Marczin N, Antonov A, Papapetropoulos A, Munn DH, Virmani R, Kolodgie FD, Gerrity R, Catravas JD. Monocyte-induced downregulation of nitric oxide synthase in cultured aortic endothelial cells. Arterioscler Thromb Vasc Biol. 16:1996;1095-1103.
12. Altman J, Dulas D, Pavek T, Laxson DD, Homans DC, Bache RJ. Endothelial function in well-developed canine coronary collateral vessels. Am J Physiol. 264:1993;H567-H572.
13. Bassenge E. Coronary vasomotor responses: role of endothelium and nitrovasodilators. Cardiovasc Drugs Ther. 8:1994;601-610.
14. Radomski MW, Palmer RMJ, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide, and prostacyclin in platelets. Br J Pharmacol. 92:1987;181-187.
15. Lüscher TF. Platelet-vessel wall interaction: role of nitric oxide, prostaglandins and endothelins. Baillieres Clin Haematol. 6:1993;609-627.
16. 2. Circulation. 89:1994;2266-2272.
17. Seccombe JF, Schaff HV. Coronary artery endothelial function after myocardial ischemia and reperfusion. Ann Thorac Surg. 60:1995;778-788.
18. Bath PM, Hassall DG, Gladwin AM, Palmer RM, Martin JF. Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb Vasc Biol. 11:1991;254-260.
19. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 90:1994;2126-2146.
20. Zeiher AM, Drexler H, Wollschläger H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 83:1991;391-401.
21. El-Tamimi H, Mansour M, Wargovich TJ, Hill JA, Kerensky RA, Conti CR, Pepine CJ. Constrictor and dilator responses to intracoronary acetylcholine in adjacent segments of the same coronary artery in patients with coronary artery disease. Endothelial function revisited. Circulation. 89:1994;45-51.
22. Yasue H, Matsuyama K, Okumura K, Morikami Y, Ogawa H. Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment: possible role of early coronary atherosclerosis. Circulation. 81:1990;482-490.
23. Zeiher AM, Schachinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation. 89:1994;2525-2532.
24. Schachinger V, Zeiher AM. Quantitative assessment of coronary vasoreactivity in humans in vivo. Importance of baseline vasomotor tone in atherosclerosis. Circulation. 92:1995;2087-2094.
25. Cox DA, Cohen ML. Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implication in atherosclerosis. Pharmacol Rev. 48:1996;3-19.
26. Jonas MA, Oates JA, Ockene JK, Hennekens CH. Statement on smoking and cardiovascular disease for health care professionals. Circulation. 86:1992;1664-1669.
27. Kugiyama K, Yasue H, Ohgushi M, Motoyama T, Kawano H, Inobe Y, Hirashima O, Sugiyama S. Deficiency in nitric oxide bioactivity in epicardial coronary arteries of cigarette smokers. J Am Coll Cardiol. 28:1996;1161-1167.
28. Zeiher AM, Schächinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilation function. Circulation. 92:1995;1094-1100.
29. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO III. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest. 95:1995;1747-1755.
30. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Yasue H. Cigarette smoke extract contracts isolated porcine coronary arteries by superoxide anion-mediated degradation of EDRF. Am J Physiol. 266:1994;H874-H880.
31. Duncker DJ, Bache RJ. Inhibition of nitric oxide production aggravates myocardial hypoperfusion during exercise in the presence of a coronary artery stenosis. Circ Res. 74:1994;629-640.
32. Tanner FC, Boulanger CM, Lüscher TF. Endothelium-derived nitric oxide, endothelin, and platelet vessel wall interaction: alterations in hypercholesterolemia and atherosclerosis. Semin Thromb Hemost. 19:1993;167-175.
33. Lin PJ, Chang CH, Lee YS, Chou YY, Chu JJ, Chang JP, Hsieh MJ. Acute endothelial reperfusion injury after coronary artery bypass grafting. Ann Thorac Surg. 58:1994;782-788.
34. Kaul S, Waack BJ, Padgett RC, Brooks RM, Heistad DD. Altered vascular responses to platelets from hypercholesterolemic humans. Circ Res. 72:1993;737-743.
35. Harlan JM, Killen PD, Senecal FM, Schwartz BR, Yee EK, Taylor RF, Beatty PG, Price TH, Ochs HD. The role of neutrophil membrane glycoprotein GP-150 in neutrophil adherence to endothelium in vitro. Blood. 66:1985;167-178.
36. Inauen W, Granger DN, Meininger CJ, Schelling ME, Granger HJ, Kvietys PR. Anoxia-reoxygenation-induced, neutrophil-mediated endothelial cell injury: role of elastase. Am J Physiol. 28:1990;H295-H231.
37. Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 320:1986;454-456.
38. Kadletz M, Dignan RJ, Loesser KE, Hess ML, Wechsler AS. Ischemia and activated neutrophils alter coronary microvascular but not epicardial coronary artery reactivity. J Thorac Cardiovasc Surg. 108:1994;648-657.
39. Abrams J. Beneficial actions of nitrates in cardiovascular disease. Am J Cardiol. 77:((suppl)):1996;31C-37C.
40. Dinerman JL, Lawson DL, Mehta JL. Interactions between nitroglycerin and endothelium in vascular smooth muscle relaxation. Am J Physiol. 1991;9265-9269.
41. Kurz MA, Lamping KG, Bates JN, Eastham CL, Marcus ML, Harrison DG. Mechanisms responsible for the heterogenous coronary microvascular response to nitroglycerin. Circ Res. 68:1991;847-855.
42. Abrams J. Therapy of angina pectoris with long-acting nitrates: which agent and when? Can J Cardiol. 12:((suppl)):1996;9C-16C.
43. Duncker DJ, Mizrahi J, Bache RJ. Nitrovasodilators ITF 296 and isosorbide dinitrate exert antiischemic activity by dilating coronary penetrating arteries. J Cardiovasc Pharmacol. 25:1995;823-832.
44. Stamler JS, Loscalzo J. The antiplatelet effects of organic nitrates and related nitroso compounds in vitro and in vivo and their relevance to cardiovascular disorders. J Am Coll Cardiol. 18:1991;1529-1536.
45. Mehta J, Mehta P. Platelet function studies in heart disease. VI. Enhanced platelet aggregate formation activity in congestive heart failure: inhibition by sodium nitroprusside. Circulation. 60:1979;497-503.
46. Hynes R, Barash PG. Infusion of sodium nitroprusside induces platelet dysfunction in vitro. Anesthesiology. 70:1989;611-615.
47. Loscalzo J. Antiplatelet and antithrombotic effects of organic nitrates. Am J Cardiol. 70:((suppl)):1992;18B-22B.
48. De Caterina R, Giannessi D, Crea F, Chierchia S, Bernini W, Gazzetti P, L'Abbate A. Inhibition of platelet function by injectable isosorbide dinitrate. Am J Cardiol. 53:1984;1683-1687.
49. Davis G, Cannizzaro S, Giubilato A, Novo S, Mattina A, Strano A. Enhanced platelet sensitivity to prostacyclin after isosorbide-5-mononitrate in patients with stable angina pectoris. Z Kardiol. 75:((suppl 3)):1986;80-82.
50. Fitzgerald DJ, Roy L, Robertson RM, FitzGerald GA. The effects of organic nitrates on prostacyclin biosynthesis and platelet function in humans. Circulation. 70:1984;297-302.
51. Hogan JC, Lewis MJ, Henderson AH. Glyceryl trinitrate and platelet aggregation: effects of N-acetylcysteine. Br J Clin Pharmacol. 27:1989;617-619.
52. Gerzer R, Drummer C, Karrenbrock B, Heim JM. Inhibition of platelet activating factor-induced platelet aggregation by molsidomine, SIN-1, and nitrates in vitro and ex vivo. J Cardiovasc Pharmacol. 14:((suppl 11)):1989;S115-S119.
53. Gogia H, Mehra A, Parikh S, Raman M, Ajit-Uppal J, Johnson JV, Elkayam U. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 26:1996;1575-1580.
54. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest. 90:1992;1168-1172.
55. Tsao PS, Theilmeier G, Singer AH, Leung LL, Cooke JP. L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 14:1994;1529-1533.
56. Bode-Böger SM, Böger RH, Creutzig A, Tsikas D, Gutzki FM, Alexander K, Frolich JC. L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci. 87:1994;303-310.
57. Egashira K, Hirooka Y, Kuga T, Mohri M, Takeshita A. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation. 94:1996;130-134.
58. Harrison DG, Armstrong ML, Feiman PC, Heistad DD. Restoration of endothelial-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 80:1987;1808-1811.
59. Lamping KG, Piegors DG, Benzuly KH, Armstrong ML, Heistad DD. Enhanced coronary vasoconstrictive response to serotonin subsides after removal of dietary cholesterol in atherosclerotic monkeys. Arterioscler Thromb Vasc Biol. 14:1994;951-957.
60. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, Takeshita A. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 89:1994;2519-2524.
61. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
62. Seiler C, Suter TM, Hess OM. Exercise-induced vasospasm of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol. 26:1995;1615-1622.
63. Anderson TJ, Meredith IT, Charbonneau F, Yeung AC, Frei B, Selwyn AP, Ganz P. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation. 93:1996;1647-1650.
64. Kjekshus J, Pedersen TR, Pyörälä K. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). (Abstr.). J Am Coll Cardiol. 29:1997;74A.